Quoin Pharmaceuticals, LTD

Quoin Pharmaceuticals announced Japan's MHLW granted Orphan Drug Designation for QRX003 lotion (4%) for Netherton Syndrome, a rare genetic skin disorder.

Quoin Pharmaceuticals announced first quarter 2026 financial results, highlighting significant regulatory progress for QRX003 in Netherton Syndrome and advancements in its QRX009 platform.

Quoin Pharmaceuticals announced its Q4 and full-year 2025 financial results, highlighted by a significant private placement financing and accelerated regulatory pathways for its lead rare disease drug, QRX003.

Quoin Pharmaceuticals has applied for Breakthrough Medicine Designation with the SFDA for QRX003, its Netherton Syndrome treatment, potentially accelerating patient access in Saudi Arabia.

Quoin Pharmaceuticals Ltd. has approved the final forms of award agreements for stock options under its 2025 Equity Incentive Plan for directors and executive officers.

Quoin Pharmaceuticals successfully achieved target loading concentrations for two topical rapamycin delivery technologies, advancing clinical development for rare diseases.

Quoin Pharmaceuticals reports a significant increase in R&D expenses for Q1 2026, alongside continued net losses and substantial doubt about its ability to continue as a going concern.

Quoin Pharmaceuticals reports increased Q3 2025 net losses and cash burn, but secures $19.9 million in new capital and gains FDA Orphan Drug Designation for QRX003.

Quoin Pharmaceuticals Ltd. reported a significant increase in net loss for Q2 2025, driven by a substantial rise in research and development expenses, raising substantial doubt about its ability to continue as a going concern.

Quoin Pharmaceuticals reports increased R&D spending and a net loss for Q1 2025, while expressing substantial doubt about its ability to continue as a going concern.

Quoin Pharmaceuticals reported a net loss of $2.35 million for the third quarter of 2024, while continuing to advance its clinical programs for rare skin diseases.

Quoin Pharmaceuticals reported a net loss of $1.97 million for the second quarter of 2024, while advancing clinical trials for its lead product, QRX003.

Quoin Pharmaceuticals reports significant clinical progress for its lead Netherton Syndrome drug QRX003, including positive Phase 2 data and FDA openness to pivotal study design, despite ongoing substantial net losses and a going concern warning.

Quoin Pharmaceuticals reports its 10-K filing, highlighting ongoing clinical trials for QRX003 in Netherton Syndrome, but also significant losses and the need for additional capital.

Quoin Pharmaceuticals' annual report on Form 10-K provides a detailed overview of the company's share structure, voting rights, and compliance with securities regulations.

Stonepine Capital Management, LLC has ceased to be a 10% beneficial owner of Quoin Pharmaceuticals, Ltd. due to an increase in outstanding shares.

Quoin Pharmaceuticals' Chief Financial Officer, Sally Bridget Lawlor, was granted 85,250 share options with an exercise price of $7.37 per ADS, vesting over four years.

Quoin Pharmaceuticals Director Joseph Cooper received 8,141 stock options with an exercise price of $7.37 per ADS, vesting over four years.

Quoin Pharmaceuticals Director Anthony James Culverwell was granted 21,709 stock options with an exercise price of $7.37 per ADS, vesting over four years.

Quoin Pharmaceuticals CEO Michael Myers was granted 318,750 share options with an exercise price of $7.37 per ADS, vesting over four years.

Quoin Pharmaceuticals' Chief Operating Officer, Denise Carter, was granted 318,750 stock options with an exercise price of $7.37 per American Depositary Share.

Quoin Pharmaceuticals Ltd. is holding its 2026 Annual General Meeting on August 20, 2026, to vote on director elections, executive compensation, director compensation program changes, 401(k) plan adjustments, and auditor appointment.

Quoin Pharmaceuticals Ltd. has called its 2025 Annual General Meeting to approve a significant increase in authorized share capital, a new executive compensation policy, and a new equity incentive plan, following a period of consistent net losses and a substantial decline in shareholder value.

Quoin Pharmaceuticals is holding its Annual General Meeting on December 5, 2024, to vote on director elections, executive compensation, amendments to the Articles of Association, and appointment of an independent auditor.

Quoin Pharmaceuticals Ltd. adjourned its Special General Meeting on March 29, 2024, due to a lack of quorum and will reconvene on April 5, 2024.

Quoin Pharmaceuticals is asking shareholders to approve the issuance of shares related to an $8 million purchase agreement with Alumni Capital LP at a special general meeting on March 29, 2024.

Quoin Pharmaceuticals is offering up to 19,230,769 ordinary shares represented by American Depositary Shares (ADSs) along with warrants in a reasonable best efforts offering.

Quoin Pharmaceuticals is launching a public offering of ordinary shares, pre-funded warrants, and common warrants to raise up to $45 million for general corporate purposes and clinical development.

Quoin Pharmaceuticals launches a best efforts offering of ADSs and warrants, aiming to raise capital for general corporate purposes, including research and development of treatments for rare skin diseases.

Quoin Pharmaceuticals is launching a public offering of ADSs and warrants, aiming to raise up to $21 million to further its research and development efforts in rare skin diseases.

Dr. Michael Myers' beneficial ownership in Quoin Pharmaceuticals Ltd. has decreased to 4.9% due to dilution from other investors exercising warrants in the company's December 2024 offering.

Denise Carter's beneficial ownership in Quoin Pharmaceuticals Ltd. decreased to 4.9% as of January 27, 2025, primarily due to the exercise of warrants by other investors in the company's December 2024 offering, which increased the total outstanding shares.

Quoin Pharmaceuticals Ltd.'s Chief Operating Officer, Denise Carter, has increased her beneficial ownership in the company to 6.9% through recent share purchases in a public offering and new option grants, as detailed in a Schedule 13D filing.

Quoin Pharmaceuticals Ltd.'s CEO and Chairman, Dr. Michael Myers, has increased his beneficial ownership in the company to 6.9% through recent purchases in a public offering and the grant of new stock options, signaling continued investment in the company's future.

Several entities affiliated with Millennium Management have reported beneficial ownership of 5.5% of Quoin Pharmaceuticals Ltd.'s ordinary shares.

ADAR1 Capital Management and Daniel Schneeberger have filed a Schedule 13G reporting a 4.9% beneficial ownership stake in Quoin Pharmaceuticals, Ltd.

Stonepine Capital Management has filed a Schedule 13G reporting a 9.99% beneficial ownership stake in Quoin Pharmaceuticals, Ltd.

Woodline Partners LP has disclosed a beneficial ownership of 4.4% of Quoin Pharmaceuticals, Ltd.'s ordinary shares, holding 2,785,370 shares as of March 31, 2026.

Aberdeen Group plc and abrdn Inc. have filed a Schedule 13G, reporting beneficial ownership of 75,000 American Depositary Shares in Quoin Pharmaceuticals, Ltd., representing 4.16% of the class.

Integrated Core Strategies (US) LLC and Millennium Management LLC, along with affiliates, reported reducing their beneficial ownership in Quoin Pharmaceuticals Ltd. to 4.6%.